

Ospedaletto di Pescantina, 21 marzo 2014

# La biopsia del linfonodo sentinella prima o dopo la chemioterapia neoadiuvante Quale impatto sulla pratica clinica

Nicla La Verde



ONCOLOGIA MEDICA E CHEMIOTERAPIA
A.O. FATEBENEFRATELLI E OFTALMICO
MILANO



#### **Axillary Staging**

- SLN surgery recommended for patients with early stage clinically node negative breast cancer
- Questions in neoadjuvant chemotherapy:
- How to clinically stage patients prior to neoadjuvant chemo?
- When and how to surgically stage the regional nodes?
  - SLN prior to chemo or after?
  - Clinically node negative
  - Clinically node positive



#### Pathologic Complete Response

#### 3 definitions:

- No residual disease in breast or axilla ypT0/N0
- No residual invasive disease in breast or axilla ypT0/N0 or ypTis/N0
- No residual invasive disease in breast ypT0 or ypTis

#### **Meta-analysis**

 pCR definition which included nodal pCR was associated with improved event-free survival and overall survival compared to ypT0/is




# How to clinically stage patients prior to neoadjiuvant chemo?



### How to clinically stage axilla in patients prior to neoadjuvant chemotherapy?





- Clinical and ultrasound N stage (N vs N1)
- From cytology (FNA) or histology (core needle biopsy) of lymph node
  - Positive cN1
  - Negative cN0



# When and how to surgically stage the regional nodes in clinically node negative (cN0) patients



#### PRIOR TO CHEMOTHERAPY

#### **Advantages**

- Classical TNM staging guides adjuvant therapy, especially post-mastectomy radiotherapy
- Accurate False negative rate known
- Chemotherapy does not interfere with axillary staging

#### **Disadvantages**

- Two operations
- If SLN is positive and perform ALND –
   will delay onset of systemic therapy
- More patients node positive more ALNDs - increased morbidity
- Loose ability to assess axillary response to chemotherapy, which is known to correlate with survival

#### **AFTER CHEMOTHERAPY**

#### **Advantages**

- One operation
- Less node positive patients less ALND - lower morbidity
- Able to assess response in axilla
- Prognostic information

#### **Disadvantages**

- Effect of chemotherapy on lymphatics unknown
- Unclear which patients should receive nodal radiation



### **SLN FN Rates**NSABP Studies

Prior to therapy (NSABP B-32)

After chemotherapy (NSABP B-27)

SLN identified 97.2%

SLN identified 85%

- with blue dye 78%
- with isotope + blue dye 89%

False negative 9.8%

False negative 10.7%

- with blue dye 14%
- with isotope + blue dye 8.4%



## Meta-analysis of SLN after Neoadjuvant Chemotherapy

21 published studies (1273 patients)

24 published studies trials (1799 patients)

- Accuracy rate .....94%
- Sensitivity .....88%
- NPV .....90%
- Identification rate...90%

- Node positive ... 37%
- SLN ID rate ...... 89.6%

False negative rate 12%

False negative rate 8,4%

Similar to without neoadjuvant chemo



### Conclusion re axillary staging for cN0 disease

- SLN after chemotherapy is as accurate as prior to chemotherapy
- SLN after chemotherapy allows informed decisions regarding further local regional therapy and systemic treatment based on the most powerful discriminator of outcome: Response



# When and how to surgically stage the regional nodes in clinically node positive (cN1) patients



#### T0-4, N1-2, M0 invasive breast cancer

(pretreatment axillary ultrasound with FNA or core biopsy documenting axillary metastases)

REGISTER\*

Neoadjuvant chemotherapy

REGISTER\*

SLN and ALND



#### **Primary aim**

To determine the false-negative rate (FNR) for SLN surgery following chemotherapy in women initially presenting with biopsy-proven cN1 breast cancer

#### **Primary endpoint**

Determine if the FNR is < 10% among women with cN1 disease who had at least 2 SLNs excised

- 10% FNR selected based on previous studies
- FNR of SLN in early breast cancer without NAC

NSABP B-32.....9.8%

FNR of SLN after NAC

NSABP B-27.....10.7%

Meta-analysis of 21 studies .....12%



#### Summary

- SLN correctly identified nodal status ....... 91.2%
- Complete pathologic nodal response rate... 40.0%
- FNR in cN1 pts with 2+ SLNs examined .... 12.6%
- FNR significantly lower with:



#### **Conclusions**

- SLN surgery is a useful tool for detection of residual nodal disease in women with node positive disease receiving NAC
- Surgical technique important to minimize FNR

Use of dual tracer

Resection of minimum of 2 SLNs

Potential further refinement with:

Clip placement in LNs at diagnosis

Pathologic review of SLNs for treatment effect

Use of SLN surgery in these patients will enable reduction in extent of axillary surgery



#### The SN FNAC study

Sentinel Node biopsy Following NeoAdjuvant Chemotherapy in biopsy proven node positive breast cancer: The SN FNAC study

- ✓ SLNs with metastases of any size (ypN0(i+) ypN1mi and ypN1) were classified positive
- ✓ March 2009 December 2012
- 153 patients enrolled



#### The SN FNAC study


- SLN identified in 127 patients (87.6%)
- 83 node positive patients
- FNR 9.6% (8/83)
- On central path review FNR only 8.4% (7/83)
- Of the 7 FN cases 4 had a single SLN resected
- FNR in 2+ SLNs removed = 4.9%
- If define ypN0(i+) as node negative, then FNR 13.3% (11/83)



#### The SN FNAC study

#### **Presenters Conclusion of SN FAC study**

- FNR (<10%) of SLN biopsy after NAC in biopsy proven node positive breast cancer is acceptable and similar to patients with clinically negative nodes in the absence of NAC
- The technical success rate of SLN biopsy (87.6%) is slightly inferior to 90%. In the presence of a technical failure, ALND is warranted
- Following NAC, SLNs with metastases of any size should be considered as positive
- The accuracy of SLN is increased when more than one node is removed



D.O.M.E.C. H. FBF - MI

#### **Conclusions from the studies**

- Approximately 40% of node positive patients convert to node negative with NAC (up to 70% in Her2+)
- SLN surgery in this setting has a FNR of 8.4%-14.2%
- Varies by definition of positive SLN, mapping technique and number of SLNs resected
- Single SLN has a high FNR in this setting in all studies
- Dual mapping agent had lower FNR in all studies
- No data per specific biological subtypes



#### Conclusions from the studies cN+

Clinical Trial	Patients Enrolled	Patients With SLN Identified	FNR Reported in Primary Paper	FNR When 2+ SLNs Resected
ACOSOG Z1071	756	637	12.6%	9.1%
SN FNAC	153	127	9.6%	4.9%
SENTINA	797	474	14.2%	9.6%

We can move to SNL biopsy after surgery



# Incorporating these recent trial results into clinical practice



### Incorporating these recent trial results into clinical practice

Oncologist: discuss trial results with multidisciplinary team at your institution

- Radiology / Surgery
   consider placement of clip in lymph nodes at time of percutaneous lymph node biopsy
- Pathology
   assessment of response to therapy effect in lymph
   nodes

# Incorporating these recent trial results into clinical practice cN0 at presentation

Staging of the regional lymph nodes with sentinel

lymph node biopsy after neoadjuvant chemotherapy

has been shown to have a similar false-negative

rate to the use of sentinel lymph node surgery

without any prior systemic therapy



# Incorporating these recent trial results into clinical practice cN1

#### Which patients to consider

- Good clinical and radiological response of disease in breast and lymph nodes
- Surgeon experience in SLN after chemotherapy

If not: go to ALND, avoiding SLNB



### Incorporating these recent trial results into clinical practice

#### At surgery

- Use dual tracer
- Resect all sentinel lymph nodes (palpable, blue, radioactive) at time of surgery
- Frozen section of SLNs
- Pathologist have to comment on presence of treatment effect in the SLNs
- If 0 SLNs or only 1 SLN convert to ALND
- If node positive proceed to ALND



